Genome&Company
KOSDAQ
₩3,250.00
-1.52%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Low debt: debt-to-equity of 0.27.
- Current assets comfortably cover current liabilities (current ratio 2.29).
- Sales have compounded about 177% a year over five years.
!Watch-points
- Thin interest cover: operating profit covers interest only about -2.5 times.
- Return on equity is on the lower side at -6.1%.
- Return on capital employed is on the lower side at -23.9%.
- The company reported a net loss in the latest period.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
-3.26
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
1 / 5
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 5 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap₩1,168억
Current Price₩ 3,250.00
High / Low₩ 10,180.00 / 2,470.00
Stock P/E-15.85
Book Value₩ 3,052.80
ROCE-23.93%
ROE-6.08%
Debt to Equity0.27
Current Ratio2.29
EPS₩ -205.00
PAT Margin-31.26%
ICR-2.49
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity